ATE472102T1 - Verfahren zur vorhersage von anomalien des lipidmetabolismus - Google Patents

Verfahren zur vorhersage von anomalien des lipidmetabolismus

Info

Publication number
ATE472102T1
ATE472102T1 AT04808108T AT04808108T ATE472102T1 AT E472102 T1 ATE472102 T1 AT E472102T1 AT 04808108 T AT04808108 T AT 04808108T AT 04808108 T AT04808108 T AT 04808108T AT E472102 T1 ATE472102 T1 AT E472102T1
Authority
AT
Austria
Prior art keywords
compound
predicting
lipidosis
abnomals
lipid metabolism
Prior art date
Application number
AT04808108T
Other languages
English (en)
Inventor
Akira Horinouchi
Ikuo Mori
Mika Murabayashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE472102T1 publication Critical patent/ATE472102T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
AT04808108T 2003-12-26 2004-12-24 Verfahren zur vorhersage von anomalien des lipidmetabolismus ATE472102T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003434151 2003-12-26
JP2004168849 2004-06-07
PCT/JP2004/019758 WO2005064344A1 (ja) 2003-12-26 2004-12-24 脂質代謝異常症の予測方法

Publications (1)

Publication Number Publication Date
ATE472102T1 true ATE472102T1 (de) 2010-07-15

Family

ID=34742146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04808108T ATE472102T1 (de) 2003-12-26 2004-12-24 Verfahren zur vorhersage von anomalien des lipidmetabolismus

Country Status (6)

Country Link
US (1) US7399638B2 (de)
EP (1) EP1710585B1 (de)
JP (1) JP4555779B2 (de)
AT (1) ATE472102T1 (de)
DE (1) DE602004027839D1 (de)
WO (1) WO2005064344A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153928A1 (en) * 2005-07-25 2008-06-26 Basf Aktiengesellschaft Method for Providing and Analyzing an Animal Population Having an Essentially Identical Metabolome
JP5005955B2 (ja) * 2006-05-24 2012-08-22 田辺三菱製薬株式会社 被験物質の脂質代謝異常症誘発可能性を予測する方法
US20110162437A1 (en) * 2006-10-09 2011-07-07 Lucette Doessegger Biomarker for Mitochondrial Toxicity Associated with Phospholipidosis
FI119745B (fi) * 2006-12-05 2009-02-27 Paavo Kinnunen Menetelmä aineen fosfolipidoosia aiheuttavien ominaisuuksien ennustamiseksi
WO2009026153A1 (en) * 2007-08-17 2009-02-26 Metabolon, Inc. Biomarkers for alzheimer's disease and methods using the same
JP5051617B2 (ja) * 2007-12-17 2012-10-17 富士電機株式会社 遠心分離方法及び遠心分離装置
US8313949B2 (en) * 2009-04-16 2012-11-20 Nextcea Inc. Detecting phospholipidosis and diagnosing lysosomal storage disorders
US9459267B2 (en) * 2014-05-12 2016-10-04 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
JP6051257B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100807A (en) 1987-10-19 1992-03-31 Abbott Laboratories Phenylacetylglutamine (pag) analytical test
JPH07104351B2 (ja) 1988-09-29 1995-11-13 株式会社日本抗体研究所 脂質代謝異常検出用キット
JPH11343300A (ja) 1998-03-13 1999-12-14 Tetsuro Fujita 新規ハプテン、それを認識する抗体およびそれらを用いた免疫学的測定法
DE69940479D1 (de) 1998-12-22 2009-04-09 Daiichi Pure Chemicals Co Ltd Monoklonaler antikörper gegen apolipoprotein a-i
US6306603B1 (en) 1999-01-08 2001-10-23 Wakunaga Phaemaceutical Co., Ltd. CD36 mutant gene and methods for diagnosing diseases caused by abnormal lipid metabolism and diagnostic kits therefor
JP2001149082A (ja) 1999-01-08 2001-06-05 Wakunaga Pharmaceut Co Ltd Cd36変異遺伝子並びに脂質代謝異常により引き起こされる疾患の判定法および診断キット
JP2001066314A (ja) 1999-06-23 2001-03-16 E Miller Norman 脂質代謝異常の検出方法及びこれを用いる疾病の検出方法

Also Published As

Publication number Publication date
US7399638B2 (en) 2008-07-15
EP1710585A4 (de) 2008-02-20
JP4555779B2 (ja) 2010-10-06
US20070166829A1 (en) 2007-07-19
WO2005064344A1 (ja) 2005-07-14
EP1710585B1 (de) 2010-06-23
EP1710585A1 (de) 2006-10-11
JPWO2005064344A1 (ja) 2007-07-19
DE602004027839D1 (de) 2010-08-05

Similar Documents

Publication Publication Date Title
Tomat et al. Imaging mobile zinc in biology
McClatchy et al. 15N metabolic labeling of mammalian tissue with slow protein turnover
Scanu et al. Evaluation of the use of human mesenchymal stem cells for acute toxicity tests
Wang et al. Gut microbiota and relevant metabolites analysis in alcohol dependent mice
MA29282B1 (fr) Procede de diagnostic d'une steatose hepatique au moyen de marqueurs biochimiques
RU2011129747A (ru) Способы, относящиеся к модифицированным гликанам
Gailus-Durner* et al. Systemic first-line phenotyping
GB0510943D0 (en) Improved immunoassay methods
ATE472102T1 (de) Verfahren zur vorhersage von anomalien des lipidmetabolismus
WO2002093129A3 (en) Methods for analyzing interactions between proteins in live and intact cells
Emson et al. A pilot study demonstrating a non-invasive method for the measurement of protein turnover in skin disorders: application to psoriasis
DE60217351D1 (de) Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens
KR101872155B1 (ko) 시스테인 검출용 이광자 형광 프로브 화합물
Ruiz-Hernández et al. Trace element and lipidomic analysis of bottlenose dolphin blubber from the Yucatan coast: Lipid composition relationships
Chiaradia et al. In slow pace towards the proteome of equine body fluids
DE60317070D1 (de) Verfahren zur diagnose von multipler sklerose
EP1043587A4 (de) Verfahren zur untersuchung von nierenkrankheiten
CN110372738A (zh) 一种定位脂滴检测硫化氢的荧光探针及其制备方法和应用
Zee et al. Quantitative imaging approaches to understanding biological processing of metal ions
DE60133997D1 (de) Verfahren zum vorhersagen von preeclampsia und anderen krankheiten
WO2012165926A3 (ko) 항-atic 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
BR0111975A (pt) Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator
JP6017724B1 (ja) 十二指腸液試料の膵液由来成分検出用試料としての適性評価方法
JP2018145111A (ja) 生体分子検出用蛍光物質
Zangarelli et al. Centrifugation-based isolation of myosin for measurement of its synthesis rate in small muscle samples

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties